1878 Gisaburo Shiono, SR., founded the company
Gisaburo Shiono, SR., founder of the company, started his career as a drug wholesaler at the present site of the head office, Doshomachi, Osaka
1892 Shionogi began manufacturing chemicals

Shionogi started to deal directly with trading firms in Europe and the US

Aspirin was first discovered in 1897 from a compound found in salicylate-bearing plants such as willow and poplar

This gave rise to the hugely important class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs)


Shionogi launched its first pharmaceutical product, Antacidin®, an antacid agent

The Shionogi logo, the Fundoh, was registered as a company trademark

The logo is called a Fundoh which is a copper weight used in Japanese scales. These weights played an important role in the development and dispensing of medicines.


Penicillin, the most famous antibiotic, was discovered

Penicillin discovered by Alexander Fleming at Saint Mary’s Medical School in London

1929 Adolf Butenandt and Edward Adelbert Doisy independently isolated the structure of oestrogen
1943 Two companies merged to create Shionogi & Co., Ltd.

Shionogi established its first company mission

“Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve”

1961 The first formal Shionogi medical research laboratories were opened
1963 Shionogi expanded into Asia, opening an office in Taiwan

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy that was discovered within the bark of the Pacific yew tree in 1967 by US researchers

Later it was found that endophytic fungi in the bark synthesize paclitaxel which is used to treat some patients with lung, ovarian, breast, head and neck cancer

1970 Shionogi launched in the US opening its first office in Los Angeles
1978 Shionogi celebrated its 100th anniversary
1988 Shionogi officially launched the Shionogi Institute for Medical Science
1992 Shionogi acquired the Eli Lilly subsidiary Qualicaps, which manufactures capsules, and started operations in the US

Consolidated US operations and established Shionogi Inc.

Established a joint venture named Shionogi- GlaxoSmithKline Pharmaceuticals LLC (later Shionogi- ViiV Healthcare LLC)

The HIV integrase inhibitor dolutegravir was discovered and developed under Shionogi-GlaxoSmithKline Pharmaceuticals LLC

2002 Launched Claritin®, a second-generation histamine antagonist used to treat allergies

Launched the hyperlipidemia treatment, Crestor®, which has been approved/marketed in over 100 countries and more than 19 million patients have been prescribed the drug worldwide

Launched the carbapenem antibiotic, Finibax®, which has been approved for use in 87 countries across the world


The Japanese initiative FINDS (PHarma-INnovation Discovery competition Shionogi) was founded

This initiative would later become the Shionogi Science Program (SSP)

Shionogi and Eli Lilly united to co-develop and co-market Cymbalta® for the treatment of a major depressive disorder and the management of diabetic peripheral neuropathic pain


Established a joint research facility with Hokkaido University, Shionogi Innovation Centre for Drug Discovery

Acquired Sciele Pharma, Inc. in the US under Shionogi Inc.

Launched the acne vulgaris treatment, Differin® which has been approved /marketed in more than 80 countries, where it has become an important therapy for more than 22 million patients since its initial launch in France in 1995


Shionogi developed a joint venture known as Ezose Sciences Inc. which provides serum glycan analysis services

Partnership with OncoTherapy Science, Inc (OTS), a biotech company was founded


Launched Rapiacta®, an antiviral drug for influenza, which delivers high plasma concentrations to the sites of infection

Launched Cymbalta® for the treatment of depression


Shionogi Science Program was launched in the UK

Opening of the Shionogi Pharmaceutical Research Centre in Osaka, Japan


Shionogi launched European headquarters based in London

Shionogi launched the injectable cancer pain analgesic, OxyFast®, an injectable formulation of oxycodone

Oxyfast® developed following a request from the Japanese Society for Palliative Medicine to address the needs of some cancer patients who have difficulty using oral therapies

The Shionogi Science Program is expanded to Australia, Belgium, Denmark, Luxembourg and Netherlands


Shionogi Science Program launched in Germany and Ireland

Ospemifene was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe dyspareunia

Shionogi Europe opens affiliate office in Italy

Shionogi Europe moves to new offices in Holborn, London


Shionogi Europe opens affiliate office in Germany

Shionogi Europe opens affiliate office in Spain

New medium term business plan "SGS 2020" starts

January 2014 ViiV Healthcare’s new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

September 2014 ViiV Healthcare’s new HIV medicine Triumeq™ (dolutegravir/ abacavir / lamivudine) is approved in Europe


Shionogi receives Marketing Authorisation approval for Senshio (ospemifene) in Europe

Shionogi receives Marketing Authorisation approval for Senshio (ospemifene) in Europe for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women

Shionogi begin to market Femal in Italy

A clinically tested dietary supplement to fight the typical symptoms of menopause such as hot flashes, night sweats, sleep disturbances, fatigue and irritability


Shionogi Announces Availability of Senshio® (ospemifene) in Spain

Shionogi announces participation in The Cambridge Therapeutics Consortium

Shionogi announces it's participation in innovative new joint research initiative, The Cambridge Therapeutics Consortium.

NP-EU-NP-0168 | August 2022